Cutaneous Melanoma Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0040978 (Cutaneous Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03842943Neoadjuvant Combination Immunotherapy for Stage III MelanomaOther
NCT03620019Denosumab + PD-1 in Subjects With Stage III/ IV MelanomaTreatment